US 8435507
Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
granted A61KA61K2039/5154A61K2039/5158
Quick answer
US patent 8435507 (Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer) held by The United States of America as Represented by the Dept. of Veterans Affairs expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Dept. of Veterans Affairs
- Grant date
- Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/5154, A61K2039/5158, A61K2039/53, A61K2039/55566